The stock price of Design Therapeutics Inc (NASDAQ: DSGN) has jumped by 14.56% compared to previous close of $3.64. Despite this, the company has seen a gain of 18.47% in its stock price over the last five trading days. globenewswire.com reported 2025-06-04 that Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the first Friedreich ataxia (FA) patient has been dosed via intravenous (IV) infusion in its RESTORE-FA (Reactivating Expression Suppressed Through Overcoming Repeat Expansion for FA) open-label Phase 1/2 multiple-ascending dose (MAD) clinical trial of DT-216P2.
Is It Worth Investing in Design Therapeutics Inc (NASDAQ: DSGN) Right Now?
Moreover, the 36-month beta value for DSGN is 1.56. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for DSGN is 30.87M and currently, short sellers hold a 11.83% of that float. On July 10, 2025, DSGN’s average trading volume was 114.46K shares.
DSGN’s Market Performance
The stock of Design Therapeutics Inc (DSGN) has seen a 18.47% increase in the past week, with a 3.99% rise in the past month, and a 32.80% gain in the past quarter. The volatility ratio for the week is 9.47%, and the volatility levels for the past 30 days are at 7.05% for DSGN. The simple moving average for the past 20 days is 10.26% for DSGN’s stock, with a -12.67% simple moving average for the past 200 days.
Analysts’ Opinion of DSGN
Many brokerage firms have already submitted their reports for DSGN stocks, with Piper Sandler repeating the rating for DSGN by listing it as a “Overweight.” The predicted price for DSGN in the upcoming period, according to Piper Sandler is $12 based on the research report published on May 07, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see DSGN reach a price target of $6, previously predicting the price at $42. The rating they have provided for DSGN stocks is “Neutral” according to the report published on November 14th, 2023.
Wedbush gave a rating of “Neutral” to DSGN, setting the target price at $6 in the report published on August 15th of the previous year.
DSGN Trading at 8.55% from the 50-Day Moving Average
After a stumble in the market that brought DSGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.33% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DSGN starting from Prasad Deepa, who sale 3,806 shares at the price of $6.27 back on Dec 18 ’24. After this action, Prasad Deepa now owns 20,000 shares of Design Therapeutics Inc, valued at $23,864 using the latest closing price.
William Arsani, the Director of Design Therapeutics Inc, sale 814,874 shares at $4.25 during a trade that took place back on Aug 09 ’24, which means that William Arsani is holding 0 shares at $3,463,214 based on the most recent closing price.
Stock Fundamentals for DSGN
The total capital return value is set at -0.3. Equity return is now at value -22.59, with -21.77 for asset returns.
Based on Design Therapeutics Inc (DSGN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -22.16.
Currently, EBITDA for the company is -48.99 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.37.
Conclusion
To wrap up, the performance of Design Therapeutics Inc (DSGN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
